Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Biologics].

× No keyword cloud information.

69 in total

1. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors: P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245

2. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

Authors: Dominique Baeten; Joachim Sieper; Jürgen Braun; Xenofon Baraliakos; Maxime Dougados; Paul Emery; Atul Deodhar; Brian Porter; Ruvie Martin; Mats Andersson; Shephard Mpofu; Hanno B Richards
Journal: N Engl J Med Date: 2015-12-24 Impact factor: 91.245

Review 3. Therapeutic advances in rheumatology with the use of recombinant proteins.

Authors: Achim Rothe; Barbara E Power; Peter J Hudson
Journal: Nat Clin Pract Rheumatol Date: 2008-09-23

Review 4. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.

Authors: Luca Semerano; Allan Thiolat; Emeline Minichiello; Gaëlle Clavel; Natacha Bessis; Marie-Christophe Boissier
Journal: Expert Opin Investig Drugs Date: 2014-04-26 Impact factor: 6.206

5. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases.

Authors: C C Mok; D van der Kleij; G J Wolbink
Journal: Clin Rheumatol Date: 2013-07-26 Impact factor: 2.980

6. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.

Authors: Charlotte L Krieckaert; Anna Jamnitski; Michael T Nurmohamed; Piet J Kostense; Maarten Boers; Gertjan Wolbink
Journal: Arthritis Rheum Date: 2012-12

7. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.

Authors: W G Dixon; K Watson; M Lunt; K L Hyrich; A J Silman; D P M Symmons
Journal: Arthritis Rheum Date: 2006-08

Review 8. Atacicept as an investigated therapy for rheumatoid arthritis.

Authors: Christophe Richez; Marie-Elise Truchetet; Thierry Schaeverbeke; Bernard Bannwarth
Journal: Expert Opin Investig Drugs Date: 2014-07-31 Impact factor: 6.206

9. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody.

Authors: G Horneff; G R Burmester; F Emmrich; J R Kalden
Journal: Arthritis Rheum Date: 1991-02

10. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.

Authors: Michela Silacci; Wibke Lembke; Richard Woods; Isabella Attinger-Toller; Nadja Baenziger-Tobler; Sarah Batey; Roger Santimaria; Ulrike von der Bey; Susann Koenig-Friedrich; Wenjuan Zha; Bernd Schlereth; Mathias Locher; Julian Bertschinger; Dragan Grabulovski
Journal: MAbs Date: 2015-09-22 Impact factor: 5.857